Ind Swift Laboratories Ltd vs Oxygenta Pharmaceutical Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 143.35 as of 05 May 16:01 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Oxygenta Pharmaceutical Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of Oxygenta Pharmaceutical Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of Oxygenta Pharmaceutical Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of Oxygenta Pharmaceutical Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Oxygenta Pharmaceutical Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990.
The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited.
Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22. The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals.
It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs.
The Company has plant located at Medak in Andhra Pradesh. The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Oxygenta Pharmaceutical Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,180 Cr while Market cap of Oxygenta Pharmaceutical Ltd is 210 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd?

As of May 5, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹135.95. On the other hand, Oxygenta Pharmaceutical Ltd stock price is INR ₹56.89.

How do dividend payouts of Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Oxygenta Pharmaceutical Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.